References: |
1. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Haring HU, Boeing H, Fritsche A.
Plasma Fetuin-A Levels and the Risk of Myocardial Infarction and Ischemic Stroke. Circulation.
2008 Nov 24;
2. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Haring HU, Schulze MB. Plasma Fetuin-A
Levels and the Risk of Type 2 Diabetes. Diabetes. 2008 Jul 15;
3. Arnaud P, Kalabay L. Alpha2-HS glycoprotein: a protein in search of a function. Diabetes Metab
Res Rev. 2002 Jul-Aug; 18(4): 311-4. Review.
4. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C,
Jahnen-Dechent W, Floege J. Association of low fetuin-A (AHSG) concentrations in serum with
cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003 Mar 8;
361(9360): 827-33.
5. Jersmann HP, Dransfield I, Hart SP. Fetuin/alpha2-HS glycoprotein enhances phagocytosis of
apoptotic cells and macropinocytosis by human macrophages. Clin Sci (Lond). 2003 Sep; 105(3):
273-8.
6. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T,
Jahnen-Dechent W. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a
systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003 Aug; 112(3): 357-66.
7. Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnen-Dechent W. Tissue distribution and
activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J.
2003 Nov 15; 376(Pt 1): 135-45.
|